UnitedHealth
UnitedHealth's revenue rose 11.8% to $447.6 billion in fiscal 2025. Its operating margin was 4.2%, down from 8.1% a year earlier. Free cash flow was $16.1 billion, down 22.4%. It paid out $13.5 billion in dividends and buybacks, 84% of free cash flow. The diluted share count fell 1.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What UnitedHealth does
UnitedHealth runs two businesses. UnitedHealthcare sells health insurance to employers, individuals, people on Medicare and people in state Medicaid programs. Optum provides health care, data and technology services, and pharmacy services to patients, doctors and hospitals, other health plans, employers, governments and drug companies.
It reports four segments: Optum Health, which delivers primary, specialty and other care and runs Optum Bank; Optum Insight, which sells data, software and consulting to hospitals, health plans and states; Optum Rx, which manages prescription drug benefits and runs pharmacies; and UnitedHealthcare. Premiums from insurance products, where it takes on the cost of members' care, make up nearly 80% of revenue. Premiums from the Centers for Medicare & Medicaid Services (CMS), which administers the Medicare Advantage program, were 44% of 2025 revenue, mostly through its Medicare plans. UnitedHealth says its competitors range from startups to large global companies, both for-profit and non-profit.
At the end of 2025 UnitedHealthcare served 29.7 million people through employer and individual plans, 8.4 million through Medicare Advantage plans and nearly 7.4 million through Medicaid and other state programs. Optum Rx managed $188 billion in drug spending in 2025. The company had more than 390,000 employees, nearly 165,000 of them clinical professionals. On January 1, 2026, it moved Optum Financial, including Optum Bank, from Optum Health into Optum Insight.
Its biggest risks, as it describes them
- Misjudging or failing to manage medical costs, which could cut the profit on its insurance products.
- Its reliance on government health programs, which brings risks from funding changes, payment adjustments, audits and investigations.
- Failing to keep good relationships with doctors, hospitals and other providers.
- Frequent lawsuits and government investigations over how it designs and delivers its products and services.
- Regulatory and operating risks in its pharmacy businesses that differ from those in the rest of the company.
Income statement
From fiscal 2016 to 2025, earnings per share grew 6.9% a year and net income 6.2% a year, as buybacks cut the share count by 6%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 23.9 | 27.9 | 29.6 | 29.1 | 28.1 |
| Debt incl. finance leases | 46.0 | 57.6 | 62.5 | 76.9 | 78.4 |
| Net debt (negative means net cash) | 22.1 | 29.7 | 32.9 | 47.8 | 50.3 |
| Net debt to EBITDA | 0.8x | 0.9x | 0.9x | 1.3x | 2.2x |
| Debt to equity | 0.6x | 0.7x | 0.7x | 0.8x | 0.8x |
| Interest coverage | 14.4x | 13.6x | 10.0x | 8.3x | 4.7x |
| Current ratio | 0.8x | 0.8x | 0.8x | 0.8x | 0.8x |
| Quick ratio | 0.8x | 0.7x | 0.8x | 0.8x | 0.8x |
Cash flow
Projections
Project UnitedHealth's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought UnitedHealth shares on the open market, and 1 insider sold $944,910.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Patrick Hugh ConwayChief Executive Officer, Optum | Sold | 1,169 | $390.00 | $455,910 | Form 4 |
| Aug 5, 2026 | Patrick Hugh ConwayChief Executive Officer, Optum | Sold | 500 | $410.00 | $205,000 | Form 4 |
| Apr 23, 2026 | Patrick Hugh ConwayChief Executive Officer, Optum | Sold | 800 | $355.00 | $284,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 7 of 9 |
| Rule of 40 | 21.6% | 12.9% | 15.4% |
| Altman Z'' | 2.01 | 1.91 | 1.41 |
| Accruals ratio | −2.6% | −3.4% | −2.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 6 of 9 | 5 of 9 | 7 of 9 |
Compare
Put UnitedHealth side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| UnitedHealth | FY25 | 11.8% | 4.2% | 3.6% | 11.2% | 2.2x | 7 | |
| HCA Healthcare | FY25 | 7.1% | — | 10.2% | 22.3% | 3.0x | 6 | Compare |
| Johnson & Johnson | FY25 | 6.0% | — | 20.9% | 28.6% | 0.7x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 184.8 | 201.2 | 226.2 | 242.2 | 257.1 | 287.6 | 324.2 | 371.6 | 400.3 | 447.6 |
| Revenue growth | 17.6% | 8.8% | 12.5% | 7.0% | 6.2% | 11.8% | 12.7% | 14.6% | 7.7% | 11.8% |
| Gross profit | 160.4 | 177.0 | 199.2 | 214.0 | 226.4 | 256.6 | 290.5 | 332.9 | 353.6 | 396.9 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 12.9 | 15.2 | 17.3 | 19.7 | 22.4 | 24.0 | 28.4 | 32.4 | 32.3 | 19.0 |
| Net income | 7.0 | 10.6 | 12.0 | 13.8 | 15.4 | 17.3 | 20.1 | 22.4 | 14.4 | 12.1 |
| Diluted EPS (US$) | 7.25 | 10.72 | 12.19 | 14.33 | 16.03 | 18.08 | 21.18 | 23.86 | 15.51 | 13.23 |
| Diluted shares (millions) | 968 | 985 | 983 | 966 | 961 | 956 | 950 | 938 | 929 | 911 |
| Cash flow | ||||||||||
| Cash from operations | 9.8 | 13.6 | 15.7 | 18.5 | 22.2 | 22.3 | 26.2 | 29.1 | 24.2 | 19.7 |
| Capital expenditure | 1.7 | 2.0 | 2.1 | 2.1 | 2.1 | 2.5 | 2.8 | 3.4 | 3.5 | 3.6 |
| Free cash flow | 8.1 | 11.6 | 13.7 | 16.4 | 20.1 | 19.9 | 23.4 | 25.7 | 20.7 | 16.1 |
| Dividends paid | 2.3 | 2.8 | 3.3 | 3.9 | 4.6 | 5.3 | 6.0 | 6.8 | 7.5 | 7.9 |
| Share buybacks | 1.3 | 1.5 | 4.5 | 5.5 | 4.2 | 5.0 | 7.0 | 8.0 | 9.0 | 5.5 |
| Acquisitions | 1.8 | 2.1 | 6.0 | 8.3 | 7.1 | 4.8 | 21.5 | 10.1 | 13.4 | 4.5 |
| Stock-based compensation | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 13.3 | 15.5 | 14.3 | 14.2 | 19.8 | 23.9 | 27.9 | 29.6 | 29.1 | 28.1 |
| Debt incl. finance leases | 33.0 | 31.7 | 36.6 | 40.7 | 43.5 | 46.0 | 57.6 | 62.5 | 76.9 | 78.4 |
| Total assets | 122.8 | 139.1 | 152.2 | 173.9 | 197.3 | 212.2 | 245.7 | 273.7 | 298.3 | 309.6 |
| Total liabilities | 82.6 | 87.0 | 96.0 | 111.7 | 126.8 | 135.7 | 159.4 | 174.8 | 195.7 | 207.9 |
| Shareholders' equity | 38.2 | 49.8 | 54.3 | 60.4 | 68.3 | 75.0 | 81.5 | 94.4 | 98.3 | 100.1 |
| Margins and ratios | ||||||||||
| Gross margin | 86.8% | 88.0% | 88.1% | 88.4% | 88.0% | 89.2% | 89.6% | 89.6% | 88.3% | 88.7% |
| Operating margin | 7.0% | 7.6% | 7.7% | 8.1% | 8.7% | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |
| Net margin | 3.8% | 5.2% | 5.3% | 5.7% | 6.0% | 6.0% | 6.2% | 6.0% | 3.6% | 2.7% |
| Free cash flow margin | 4.4% | 5.8% | 6.0% | 6.8% | 7.8% | 6.9% | 7.2% | 6.9% | 5.2% | 3.6% |
| Rule of 40 (growth + FCF margin) | 22.0% | 14.6% | 18.5% | 13.8% | 14.0% | 18.8% | 19.9% | 21.6% | 12.9% | 15.4% |
| Return on capital | 13.9% | 18.9% | 18.9% | 19.1% | 19.0% | 20.1% | 21.4% | 21.6% | 17.9% | 11.2% |
| Return on equity | 19.5% | 24.0% | 23.0% | 24.1% | 23.9% | 24.1% | 25.7% | 25.4% | 14.9% | 12.2% |
| Return on assets | 6.0% | 8.1% | 8.2% | 8.5% | 8.3% | 8.4% | 8.8% | 8.6% | 5.0% | 4.0% |
| Net debt to EBITDA | 1.3x | 0.9x | 1.1x | 1.2x | 0.9x | 0.8x | 0.9x | 0.9x | 1.3x | 2.2x |